Related Experiment Videos
[Glial volume test for patients with schizophrenia and its changes during therapy]
Zhurnal Nevropatologii I Psikhiatrii Imeni S.S. Korsakova (Moscow, Russia : 1952)
|January 1, 1989
Summary
The Glial Volume Test (GVT) measures antibrain antibodies in central nervous system disorders. GVT changes correlate with disease severity and treatment outcomes, serving as a prognostic tool.
Area of Science:
- Neuroscience
- Immunology
- Psychiatry
Context:
- Schizophrenia and organic central nervous system (CNS) disorders are complex conditions.
- Assessing disease activity and treatment response in these disorders remains challenging.
- Cytotoxic antibrain antibodies are implicated in CNS pathology.
Purpose:
- To evaluate the Glial Volume Test (GVT) as a method for assessing cytotoxic antibrain antibodies.
- To determine the correlation between GVT changes and the course of schizophrenic and organic CNS disorders.
- To investigate the prognostic value of GVT in predicting treatment efficiency.
Summary:
- The Glial Volume Test (GVT) was employed in 64 schizophrenic patients and 42 patients with organic CNS disorders.
- GVT changes were found to be non-specific, reflecting the overall disease progression.
- Increased serum cytotoxicity correlated with heightened psychopathological signs, while alleviation led to normalized GVT levels.
- Treatment outcomes were dependent on baseline GVT levels.
Impact:
- The GVT demonstrates potential as an objective prognostic criterion for disease course in CNS disorders.
- The test may aid in evaluating treatment efficiency and guiding clinical management.
- Findings contribute to understanding the role of cytotoxic antibrain antibodies in neuropsychiatric conditions.